Posted by Michael Wonder on 24 May 2022
FDA approves Dermavant’s Vtama (tapinarof) 1% cream for the treatment of plaque psoriasis in adults: first topical novel chemical entity launched for psoriasis in the U.S. in 25 years
23 May 2022 - In the pivotal Phase 3 clinical trial program, Vtama cream met all primary and secondary endpoints and demonstrated highly statistically significant improvement versus vehicle in Physician Global Assessment score with 36% of patients versus 6% in vehicle in PSOARING 1 and 40% of patients versus 6% in vehicle in PSOARING 2 achieving clear or almost clear with a minimum 2-grade improvement at week 12 (p<0.0001 for both trials).
Dermavant Sciences today announced that the U.S. FDA has approved Vtama (tapinarof) 1% cream, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults.
